Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CTSL | P07711 | 4/20 | 0.60 |
| ▸ | CTSK | P43235 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 3/20 | 0.59 |
| ▸ | CTSC | P53634 | 3/20 | 0.59 |
| ▸ | CTSB | P07858 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31163204 | 0.98 | HTT (0.64) | HTTMAPK1ALDH1A1LMNAKMT2A | |
| SCHEMBL266924 | 0.98 | HTT (0.64) | HTTMAPK1ALDH1A1LMNAKMT2A | |
| SCHEMBL3409484 | 0.95 | CTSL (0.61) | HTTMAPK1ALDH1A1LMNAKMT2A | |
| SCHEMBL15688099 | 0.92 | CTSL (0.64) | HTTMAPK1ALDH1A1LMNAKMT2A | |
| SCHEMBL23048255 | 0.85 | CTSL (0.57) | HTTMAPK1ALDH1A1LMNAKMT2A | |
| SCHEMBL3712567 | 0.83 | CTSL (0.53) | HTTMAPK1ALDH1A1LMNAKMT2A | |
| SCHEMBL23052298 | 0.81 | CTSL (0.64) | HTTMAPK1ALDH1A1LMNACTSL | |
| SCHEMBL8015470 | 0.81 | ALDH1A1 (0.67) | HTTMAPK1ALDH1A1LMNAKMT2A | |
| SCHEMBL10082160 | 0.80 | MAPK1 (1.00) | HTTMAPK1ALDH1A1LMNAKMT2A | |
| SCHEMBL2834532 | 0.80 | MAPK1 (1.00) | HTTMAPK1ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8604042-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1951684-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1844011-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2006081343-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, CYSLTR2 | HTT 3945/4885MAPK1 3444/4885ALDH1A1 1779/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | HTT 3657/4885MAPK1 298/4885ALDH1A1 3235/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | HTT 3657/4885MAPK1 298/4885ALDH1A1 3235/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | HTT 3657/4885MAPK1 298/4885ALDH1A1 3235/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | HTT 3657/4885MAPK1 298/4885ALDH1A1 3235/4885 |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | HTT 122/4885MAPK1 4602/4885ALDH1A1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.